Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/44024
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTam C.S.-
dc.contributor.authorOpat S.-
dc.contributor.authorSimpson D.-
dc.contributor.authorCull G.-
dc.contributor.authorMunoz J.-
dc.contributor.authorPhillips T.J.-
dc.contributor.authorKim W.S.-
dc.contributor.authorRule S.-
dc.contributor.authorAtwal S.K.-
dc.contributor.authorWei R.-
dc.contributor.authorNovotny W.-
dc.contributor.authorHuang J.-
dc.contributor.authorWang M.-
dc.contributor.authorTrotman J.-
dc.date.accessioned2022-02-09T05:19:32Z-
dc.date.available2022-02-09T05:19:32Z-
dc.date.copyright2021-
dc.date.issued2021-12-17en
dc.identifier.citationBlood Advances. 5(12) (pp 2577-2585), 2021. Date of Publication: 22 Jun 2021.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/44024-
dc.description.abstractZanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was administered as 160 mg twice daily (n 5 14), 320 mg once daily (n 5 18), or #160 mg total dose (n 5 5). Herein, we report results for patients receiving a total daily dose of 320 mg (N 5 32). Median study follow-up was 18.8 months. Eighteen patients discontinued treatment, 10 because of progressive disease and 8 because of adverse events (AEs); 1 AE (peripheral edema) was considered to be related to zanubrutinib treatment. The most common AEs were diarrhea (43.8%), contusion (37.5%), constipation (31.3%), and upper respiratory tract infection (31.3%). Infection was the most commonly reported AE of interest (18.8% of patients experienced grade $3 infection). At least 1 AE of grade $3 was reported in 59.4% of patients; grade $3 AEs that were reported in .2 patients were anemia (12.5%), pneumonia (9.4%), and myalgia (9.4%). Overall response rate was 84%, with 25% achieving a complete response. Median duration of response was 18.5 months. Median progression-free survival (PFS) was 21.1 months. Zanubrutinib was well tolerated and demonstrated activity in patients with R/R MCL. The trial is registered at www.clinicaltrials.gov as #NCT02343120.Copyright © 2021 American Society of Hematology. All rights reserved.-
dc.publisherAmerican Society of Hematology-
dc.relation.ispartofBlood Advances-
dc.subject.meshacute kidney failure-
dc.subject.meshallogeneic stem cell transplantation-
dc.subject.meshANCA associated vasculitis-
dc.subject.meshanemia-
dc.subject.meshapoptosis-
dc.subject.meshatrial fibrillation-
dc.subject.meshbone marrow biopsy-
dc.subject.meshbrain infarction-
dc.subject.meshcancer survival-
dc.subject.meshcomputer assisted tomography-
dc.subject.meshcongestive heart failure-
dc.subject.meshconstipation-
dc.subject.meshcontusion-
dc.subject.meshdiarrhea-
dc.subject.meshdiffuse large B cell lymphoma-
dc.subject.meshdrug dose reduction-
dc.subject.meshdrug efficacy-
dc.subject.meshdrug safety-
dc.subject.meshdrug tolerability-
dc.subject.meshdrug withdrawal-
dc.subject.meshepistaxis-
dc.subject.meshhematoma-
dc.subject.meshhematuria-
dc.subject.meshhypertension-
dc.subject.meshischemic heart disease-
dc.subject.meshmantle cell lymphoma-
dc.subject.meshmaximum tolerated dose-
dc.subject.meshmyalgia-
dc.subject.meshmyelodysplastic syndrome-
dc.subject.meshneutropenia-
dc.subject.meshperipheral edema-
dc.subject.meshpneumonia-
dc.subject.meshprogression free survival-
dc.subject.meshrecommended drug dose-
dc.subject.meshseptic shock-
dc.subject.meshthrombocytopenia-
dc.subject.meshupper respiratory tract infection-
dc.subject.meshbendamustine-
dc.subject.meshbilirubin-
dc.subject.meshbortezomib-
dc.subject.meshrituximab-
dc.subject.meshvoriconazole-
dc.subject.meshwarfarin-
dc.subject.meshzanubrutinib-
dc.subject.meshzanubrutinib/ct-
dc.subject.meshcomputed tomography scanner-
dc.subject.meshPET-CT scanner-
dc.titleZanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.-
dc.typeArticle-
dc.identifier.affiliationHaematology-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1182/bloodadvances.2020004074-
dc.publisher.placeUnited States-
dc.identifier.pubmedid34152395 [https://www.ncbi.nlm.nih.gov/pubmed/?term=34152395]-
dc.identifier.institution(Opat) Monash Health, Clayton, VIC, Australiaen
dc.identifier.institution(Tam) Peter MacCallum Cancer Centre, Melbourne, VIC, Australiaen
dc.identifier.institution(Tam) St Vincent s Hospital, Fitzroy, VIC, Australiaen
dc.identifier.institution(Tam) Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australiaen
dc.identifier.institution(Tam) Royal Melbourne Hospital, Parkville, VIC, Australiaen
dc.identifier.institution(Opat) Department of Haematology, Monash University, Clayton, VIC, Australiaen
dc.identifier.institution(Simpson) North Shore Hospital, Auckland, New Zealanden
dc.identifier.institution(Simpson, Atwal, Wei, Novotny, Huang) BeiGene USA, Inc, San Mateo, CA, United Statesen
dc.identifier.institution(Cull) Sir Charles Gairdner Hospital, Perth, WA, Australiaen
dc.identifier.institution(Cull) Pathology and Laboratory Medicine, University of Western Australia, Perth, WA, Australiaen
dc.identifier.institution(Munoz) Banner MD Anderson Cancer Center, Gilbert, AZ, United Statesen
dc.identifier.institution(Phillips) Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United Statesen
dc.identifier.institution(Kim) Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Koreaen
dc.identifier.institution(Rule) Peninsula Medical School, University of Plymouth, Plymouth, United Kingdomen
dc.identifier.institution(Wang) University of Texas MD Anderson Cancer Center, Houston, TX, United Statesen
dc.identifier.institution(Trotman) Concord Repatriation Hospital, University of Sydney, Sydney, NSW, Australiaen
dc.subect.keywordsadult-
dc.subect.keywordsarticle-
dc.subect.keywordsclinical article-
dc.subect.keywordsclinical trial-
dc.subect.keywordsfemale-
dc.subect.keywordsfollow up-
dc.subect.keywordshuman-
dc.subect.keywordsmale-
dc.identifier.affiliationext(Tam) Peter MacCallum Cancer Centre, Melbourne, VIC, Australia-
dc.identifier.affiliationext(Tam) St Vincent s Hospital, Fitzroy, VIC, Australia-
dc.identifier.affiliationext(Tam) Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia-
dc.identifier.affiliationext(Tam) Royal Melbourne Hospital, Parkville, VIC, Australia-
dc.identifier.affiliationext(Opat) Department of Haematology, Monash University, Clayton, VIC, Australia-
dc.identifier.affiliationext(Simpson) North Shore Hospital, Auckland, New Zealand-
dc.identifier.affiliationext(Simpson, Atwal, Wei, Novotny, Huang) BeiGene USA, Inc, San Mateo, CA, United States-
dc.identifier.affiliationext(Cull) Sir Charles Gairdner Hospital, Perth, WA, Australia-
dc.identifier.affiliationext(Cull) Pathology and Laboratory Medicine, University of Western Australia, Perth, WA, Australia-
dc.identifier.affiliationext(Munoz) Banner MD Anderson Cancer Center, Gilbert, AZ, United States-
dc.identifier.affiliationext(Phillips) Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United States-
dc.identifier.affiliationext(Kim) Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea-
dc.identifier.affiliationext(Rule) Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom-
dc.identifier.affiliationext(Wang) University of Texas MD Anderson Cancer Center, Houston, TX, United States-
dc.identifier.affiliationext(Trotman) Concord Repatriation Hospital, University of Sydney, Sydney, NSW, Australia-
dc.identifier.affiliationmh(Opat) Monash Health, Clayton, VIC, Australia-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptHaematology-
Appears in Collections:Articles
Show simple item record

Page view(s)

56
checked on Mar 15, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.